Formally established by the institution in 2006 to address the growing demand for bioinformatics expertise at Mayo Clinic, the Bioinformatics Core Shared Resource (BIC) is a new shared resource of the Cancer Center. The mission of the Shared Resource is to assist Mayo Clinic Cancer Center (MCCC) investigators in leveraging intramural and extramural sources of biological information to promote discoveries that will impact patient care. To this end, the BIC offers a suite of services to support investigators with the manipulation, preprocessing, and interpretation of genomics, microarray, and proteomics data. These services include: sequence analysis and comparative genomics;gene and SNP selection for association studies;data parsing and formatting;gene ID conversion, biological pathway and networks analysis;data preprocessing;including quality control;and management and education regarding public and local databases and bioinformatics applications. BIC has assembled a team of 13 computer scientists and 12 bioinformatics experts who work collaboratively with biostatisticians to provide analytical support to investigators at all three Mayo campuses. NCI related goals for bioinformatics is assured by dedicated Shared Resource support for the evaluation and integration of caBIG projects into Mayo's infrastructure. BIC provides critical 'value-add'to MCCC investigators in providing (i) investigator support during planning and execution of high throughput experiments;(ii) development of bioinformatics tools and education programs;and (iii) infrastructure for experimental techniques and analytical methods validation, including quality control workflows for genotyping data, preprocessing workflows for gene expression profiles, validation of copy number variation, and high throughput sequencing;and platforms for data integration and mining. Over the past year, BIC has supported 36 MCCC investigators, accounting for more than 50% of the Shared Resource's total usage, and offered 22 classes and training programs attended by more than 40 MCCC investigators and personnel.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-39
Application #
8465664
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
39
Fiscal Year
2013
Total Cost
$226,952
Indirect Cost
$69,834
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547

Showing the most recent 10 out of 1129 publications